495 -- Recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month". | Poliscope
Recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month".
Recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month".
vs 1,187 other HRES bills in the 115th — cohort avg 17d
Summary
Expresses support for the goals and ideals of Polycystic Ovary Syndrome (PCOS) Awareness Month. (PCOS is caused by a hormone imbalance. Symptoms can include infertility, weight gain, excess hair growth, and acne.) Recognizes the need for further research, improved treatment and care options, and a cure for PCOS. Acknowledges the struggles affecting all women and girls afflicted with PCOS.
Lobbying filings that explicitly cite this bill (7)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Cited source text, amounts, lobbyists, and targets
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3268/S. 1603).
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268).
Supported H. Res. 495, recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month".
Support maintaining the Prevention and Public Health Fund (PPHF).
Advocate for The National Hansens Disease Program funding in H.R. 1628, Consolidated Appropriations Act, 2018.
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration in FY19 Labor/HHS/Education Appropriations (Bill TBD)
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (H.R. 1628, Consolidated Appropriations Act, 2018)
Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to reducing PPHF in H.R.1892.
Cited source text, amounts, lobbyists, and targets
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3268/S. 1603).
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268).
Supported H. Res. 495, recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month".
Support maintaining the Prevention and Public Health Fund (PPHF).
Advocate for The National Hansens Disease Program funding in H.R. 1628, Consolidated Appropriations Act, 2018.
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration in FY19 Labor/HHS/Education Appropriations (Bill TBD)
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (H.R. 1628, Consolidated Appropriations Act, 2018)
Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to reducing PPHF in H.R.1892.
Client expense: $470,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3268/S. 1603).
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3268).
Supported H. Res. 495, recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month".
Support maintaining the Prevention and Public Health Fund (PPHF).
Client expense: $340,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cited source text, amounts, lobbyists, and targets
Letter to senators who sponsored a Graham/Cassidy proposal that would repeal and amend provisions of the Patient Protection and Affordable Care Act to share concerns that their proposed changes would result in reductions in health care coverage, particularly for individuals with substance use disorders and mental illness.
Letter to sponsors supporting HR 3255/S 2122 the Supporting Working Moms Act.
Letter to sponsors supporting HR 2375/S 1110 the Friendly Airports for Mothers Act.
Letter to senators urging them to vote no on the Graham-Cassidy-Heller-Johnson bill.
Letter to House and Senate majority and minority leaders as well as the chair and ranking members of both the Senate Finance Committee and the House Energy and Commerce Committee urging reauthorizing expired healthcare programs: the Children's Health Insurance Program (CHIP), Community Health Centers (CHCs), Medicaid Disproportionate Share Hospital (DSH) payments, the Maternal and Infant Early Childhood Home Visiting Program (MIECHV), and the National Health Service Corps (NHSC).
Letter to senators and representatives urging support for S Res 336/H Res 495 Recognizing the Seriousness of Polycystic Ovary Syndrome.
Comments to Dept. of Veteran's Affairs on proposed rule that would increase access to quality health care for our nations veterans by expanding telehealth services.
Thanking Representatives for introducing the Addiction Treatment Access Improvement Act of 2017 (H.R. 3692).
Meetings with House staff on H.R.959 - Title VIII Nursing Workforce Reauthorization Act of 2017.
Meetings with House staff about maternal and infant healthcare issues.
Meetings with House staff about HR 1318 Preventing Maternal Deaths Act.
Meetings with Senate staff about S 1112 Maternal Mortality Accountability Act.
Client expense: Not reported · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Health Insurance Coverage (general); Genetic Screening and Testing (general); Health Disparities (general); Emergency Contraception (general); Breastfeeding (general); Pregnancy Intention (general); Smoking Cessation (general); Substance Use Disorder (general); Gynecologic Cancer (general); Gynecologic Devices (general); Reproductive Health (general); Domestic Violence (general); Gun Violence (general); Immunization (general); Breast Cancer (general); E-Cigarettes (general); Medical Liability Reform (general); Health IT (general); Patient-Physician Relationship (general); Child Welfare (general); Prematurity (general); Health Disparities (general); Prevention and Public Health Fund (general); Maternal Mortality and Morbidity (general); Imaging (general); Graduate Medical Education (general); Lab Developed Tests (general); Stem Cell Research (general); Contraception (general); Preeclampsia (general); National Health Service Corps (general); Community Health Centers (general); Abortion (general); Indian Health (general); Teaching Health Centers (general); H.R.3394/S. 1754, Teaching Health Centers Graduate Medical Education Extension Act of 2017/Training the Next Generation of Primary Care Doctors Act of 2017; Teen Pregnancy Prevention Program (general); Research in Pregnant and Breastfeeding Women (general); Healthy Start (general); Zika Virus (general); Health Care Reform (general); H.R.__/S. ___ Quality Care for Moms and Babies Act; H.R. 1318/S 1112, Preventing Maternal Deaths Act/Maternal Health Accountability Act; H.R. 1876/S. 781, Good Samaritan Health Professionals Act; H.R. 1215/S.___ Protecting Access to Care Act; H.R. 1704, Accessible Care by Curbing Excessive Lawsuits (ACCESS) Act; H.R. 1565, Saving Lives, Saving Costs Act;; H.R. 3120, To amend title XVIII of the Social Security Act to reduce the volume of future electronic health record-related significant hardship requests; H.R. 315/S. 783, Improving Access to Maternity Care Act; S. Res. 319, a resolution supporting the goals, activities, and ideals of Prematurity Awareness Month; H.Res. 495/S.Res. 336, a resolution recognizing the seriousness of Polycystic Ovary Syndrome; Hyde Amendment (General);; H.R. 671/ S. 210, the Global Health Empowerment and Rights (Global HER) Act; HR 4418, the Enhancing Questions to Understand Intentions for Pregnancy (EQUIP) Act of 2017; H.R. 3602/S. 1653, Real Education for Healthy Youth Act; H.R. 421/S. 93, Allowing Greater Access to Safe and Effective Contraception Act; H. Res. 205, expressing the sense of the House of Representatives with respect to ensuring that womens health care under current law is preserved; H.R. 2567/ S. 2259, Access to Birth Control (ABC) Act; H.R. 4082/S. 1985, Protect Access to Birth Control Act; H.R. 490, Heartbeat Protection Act; H.R. 36, Pain-Capable Unborn Child Protection Act; H.R. 3842, Healthy Start Reauthorization Act; H.R.__/S. ___, the PREEMIE Reauthorization Act; H.R. 3692, Addiction Treatment Access Improvement Act;; H.R. 253/S. 1268, Family First Prevention Services Act/Child Protection and Family Support Act; H.R. 2545/S. 747, Special Diabetes Program for Indians Reauthorization Act; Personal Responsibility Education Program (general); Womens Preventive Services (general); S. ___, Bipartisan Heath Care Stabilization Act; H.R. ____, CHAMPION Act; H.R. 4101, School Milk Nutrition Act; H.R. 2417/ S. 1101, Pregnant Workers Fairness Act; Implementation of P.L. 114-91, Protecting Our Infants Act; Implementation of P.L. 114-198, Comprehensive Addiction and Recovery Act; Implementation of P.L. 114-255, 21st Century Cures Act.
Cited source text, amounts, lobbyists, and targets
Advocate for medical research funding at the National Institutes of Health, National Cancer Institute, NIAMS, Centers for Disease Control and Prevention, Agency for Healthcare Research and Quality, and Food and Drug Administration (FY 18 Labor/HHS/Education Appropriations, H.R. 3358/S. 1771, and FY 18 Agriculture Appropriations bills, H.R. 3628/S. 1603).
Educate members of Congress regarding Carter Amendment (#7) to Division B of Rules Committee Print 115-31 related to access to compounded medications (H.R. 3628, FY 18 Agriculture Appropriations Bill).
Advocate for the inclusion of Congressional Directed Medical Research Programs in the 2018 National Defense Authorization Act (S. 1519/H.R. 2810). Advocate against Sections 733, 891, 892, and 893 in S. 1519, which would impact CDMRP.
Lobby members of Congress to direct the FDA to issue rulemaking pertaining to physicians access to compounded medications for use in the physician office setting (H.R. 3628).
Supported H. Res. 495, recognizing the seriousness of Polycystic Ovary Syndrome (PCOS) and expressing support for the designation of the month of September 2017 as "PCOS Awareness Month".
Support maintaining the Prevention and Public Health Fund (PPHF); opposed provisions to repeal the PHHF in H.R. 1628 (American Health Care Act/Better Care Reconciliation Act).
Client expense: $460,000 · Firm income: Not reported
Government targets: Administration for Children & Families (ACF), Agency for Healthcare Research & Quality (AHRQ), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Homeland Security, Dept of (DHS), Indian Health Service, Justice, Dept of (DOJ), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Natl Drug Control Policy (NDCP), SENATE, State, Dept of (DOS), Substance Abuse & Mental Health Services Administration (SAMHSA), U.S. Agency for International Development (USAID), Veterans Affairs, Dept of (VA), White House Office
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE